555 related articles for article (PubMed ID: 25734957)
21. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
22. Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
[TBL] [Abstract][Full Text] [Related]
23. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
24. Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Tello-Montoliu A; Thano E; Rollini F; Patel R; Wilson RE; Muñiz-Lozano A; Franchi F; Darlington A; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2013 Oct; 110(4):777-84. PubMed ID: 23884248
[TBL] [Abstract][Full Text] [Related]
25. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
26. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
27. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
28. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
30. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
[TBL] [Abstract][Full Text] [Related]
31. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
32. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
33. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
McGlasson DL; Shah AD; Fritsma GA
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):583-7. PubMed ID: 21799401
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Fox SC; Behan MW; Heptinstall S
Cell Calcium; 2004 Jan; 35(1):39-46. PubMed ID: 14670370
[TBL] [Abstract][Full Text] [Related]
35. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
36. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
Kikura M; Kazama T; Ikeda T; Sato S
Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
[TBL] [Abstract][Full Text] [Related]
37. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the aggregation responses of camel platelets.
Al Ghumlas AK; Gader AG
Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
[TBL] [Abstract][Full Text] [Related]
39. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
[TBL] [Abstract][Full Text] [Related]
40. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]